
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

